考虑限价政策和公益性的药品供应链定价与渠道策略分析

发布时间：2018-04-02 05:02

本文选题：药品供应链　切入点：定价　出处：《中国管理科学》2017年12期

【摘要】：针对药品供应商在线售药而引发的渠道冲突现象,考虑我国药品限价政策、医疗机构公益性,构建了药品供应商、医疗机构组成的药品供应链在不同渠道策略下理论模型。进而分析限价政策、公益性等因素对均衡的影响,然后提出了药品供应商的最优渠道策略。研究发现:当药品价格受到管制时,降低最高限价有利于增加供应链利润,提高社会整体福利;当药品价格不受管制时,增加医疗机构公益性有利于降低药品价格,提高药品供应链利润和社会福利;当最高限价偏低时,药品供应商在线渠道开辟所引发的与医疗机构间矛盾将不能通过供应链内部协调;而当药品价格不受管制时,二者矛盾不仅可以通过供应链利润内部转移机制协调,而且可以达到药品供应商、医疗机构和患者的三赢。最后,解析了当前我国药品政策,并提出了相应的管理学启示。
[Abstract]:In view of the channel conflict caused by online drug selling by drug suppliers, considering the policy of drug price limit and the public welfare of medical institutions, a theoretical model of pharmaceutical supply chain composed of drug suppliers and medical institutions is constructed under different channel strategies.Then it analyzes the influence of price limit policy, public welfare and other factors on the equilibrium, and then puts forward the optimal channel strategy for drug suppliers.The study found that when the drug price is regulated, reducing the maximum price will increase the profit of the supply chain and improve the overall welfare of the society; when the drug price is not regulated, increasing the public welfare of the medical institution will help to reduce the drug price.Improve the profit and social welfare of the pharmaceutical supply chain; when the maximum price is low, the contradiction with the medical institutions caused by the opening of online channels for drug suppliers will not be coordinated through the supply chain; and when the price of drugs is not regulated,The contradiction can not only be coordinated through the internal transfer mechanism of the profit in the supply chain, but also can achieve the triple win of drug suppliers, medical institutions and patients.Finally, the current drug policy of our country is analyzed, and the corresponding enlightenment of management is put forward.
【作者单位】：重庆大学经济与工商管理学院;重庆大学现代物流重庆市重点实验室;深圳大学管理学院;
【基金】：国家自然科学基金资助项目(71572020,71272086)
【分类号】：F274;F426.72

【相似文献】